Form 4: Catheter Precision Grants Options to Exec. Chairman

Catheter Precision, Inc. has granted 500,000 stock options to Executive Chairman David A. Jenkins, aligning executive incentives with long-term company performance.

Summary

• David A. Jenkins, the Executive Chairman of the Board and a Director of Catheter Precision, Inc. (VTAK), was granted 500,000 stock options.
• The options have an exercise price of $0.18 per share.
• The grant date for these options is August 12, 2025.
• The options will vest at a rate of 20% per year, beginning on the first anniversary of the grant date.
• The options have an expiration date of August 12, 2035.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as the options grant aligns executive interests with shareholder value, which is a standard and generally beneficial practice for corporate governance and long-term performance.

Positives

• The grant of stock options to the Executive Chairman aligns his financial interests with the long-term performance and shareholder value of Catheter Precision, Inc.
• This is a standard form of executive compensation designed to incentivize leadership.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders, although this is a common aspect of equity compensation plans.

Future Outlook

The options grant incentivizes the Executive Chairman to contribute to the company's long-term growth and success, as the value of the options is tied to the future stock price performance.

Industry Context

This options grant is a routine executive compensation practice within the medical device industry, aiming to retain and motivate key leadership by linking their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of stock options to executive leadership is a common practice across publicly traded companies, including those in the medical device sector, to align management incentives with shareholder interests.
• The vesting schedule of 20% per year over five years is a typical structure for long-term incentive plans, comparable to those seen at companies like Medtronic (MDT) or Boston Scientific (BSX) for similar executive roles, though the specific number of options and exercise price would vary based on company size and compensation philosophy.

Related Party Transactions

• The grant of 500,000 stock options to David A. Jenkins, the Executive Chairman of the Board, constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for long-term value creation due to incentivized management, balanced against potential future dilution from option exercise.
• Management: Increased incentive to drive company performance and stock price appreciation.

Next Steps

• The options will begin to vest at 20% per year starting on August 12, 2026, continuing annually until fully vested.

Key Dates

Keywords

Catheter Precision, VTAK, Stock Options, Executive Compensation, Insider Transaction, Form 4, David A. Jenkins, Medical Devices, Corporate Governance